CNS Pharmaceuticals, Inc. (CNSP) stock
CNSPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.15+0.67 (+19.25%)
Close on Nov 17, 2026Market cap $6.07MP/E –Yield –
CNS Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
CNS Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $10.11M, down 0.5% year over year. For fiscal 2025 it was $9.77M, up 5.2% from the year before. The highest annual figure on record is $14.10M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.77M | +5.2% |
| FY2024 | Dec 31, 2024 | $9.29M | -34.1% |
| FY2023 | Dec 31, 2023 | $14.10M | +51.6% |
| FY2022 | Dec 31, 2022 | $9.30M | -5.2% |
| FY2021 | Dec 31, 2021 | $9.81M | +93.7% |
| FY2020 | Dec 31, 2020 | $5.06M | +173.0% |
| FY2019 | Dec 31, 2019 | $1.85M | +8619.3% |
| FY2018 | Dec 31, 2018 | $21.27K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.20M | +2.9% |
| Q1 FY2026 | Mar 31, 2026 | $3.54M | +9.3% |
| Q4 FY2025 | Dec 31, 2025 | $3.17M | +111.3% |
| Q3 FY2025 | Sep 30, 2025 | $2.20M | -48.2% |
| Q2 FY2025 | Jun 30, 2025 | $1.17M | +4.5% |
| Q1 FY2025 | Mar 31, 2025 | $3.24M | +33.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.50M | -64.9% |
| Q3 FY2024 | Sep 30, 2024 | $4.24M | +24.5% |
| Q2 FY2024 | Jun 30, 2024 | $1.12M | -60.8% |
| Q1 FY2024 | Mar 31, 2024 | $2.43M | -31.9% |
| Q4 FY2023 | Dec 31, 2023 | $4.27M | +43.3% |
| Q3 FY2023 | Sep 30, 2023 | $3.41M | +54.5% |
| Q2 FY2023 | Jun 30, 2023 | $2.85M | +28.1% |
| Q1 FY2023 | Mar 31, 2023 | $3.57M | +88.9% |
| Q4 FY2022 | Dec 31, 2022 | $2.98M | +26.6% |
| Q3 FY2022 | Sep 30, 2022 | $2.21M | -14.4% |
| Q2 FY2022 | Jun 30, 2022 | $2.22M | -16.6% |
| Q1 FY2022 | Mar 31, 2022 | $1.89M | -14.4% |
| Q4 FY2021 | Dec 31, 2021 | $2.36M | +23.0% |
| Q3 FY2021 | Sep 30, 2021 | $2.58M | +147.3% |
| Q2 FY2021 | Jun 30, 2021 | $2.66M | +78.6% |
| Q1 FY2021 | Mar 31, 2021 | $2.21M | +260.0% |
| Q4 FY2020 | Dec 31, 2020 | $1.91M | +33.1% |
| Q3 FY2020 | Sep 30, 2020 | $1.04M | +220.1% |
| Q2 FY2020 | Jun 30, 2020 | $1.49M | +3392.4% |
| Q1 FY2020 | Mar 31, 2020 | $613.08K | +1169.1% |
| Q4 FY2019 | Dec 31, 2019 | $1.44M | – |
| Q3 FY2019 | Sep 30, 2019 | $325.63K | +6979.0% |
| Q2 FY2019 | Jun 30, 2019 | $42.73K | – |
| Q1 FY2019 | Mar 31, 2019 | $48.31K | – |
| Q4 FY2018 | Dec 31, 2018 | $0 | – |
| Q3 FY2018 | Sep 30, 2018 | $4.60K | – |
See a number that looks wrong?